Logo image of MDXH.BR

MDxHealth SA (MDXH.BR) Stock Fundamental Analysis

EBR:MDXH - Euronext Brussels - BE0974461940 - Common Stock - Currency: EUR

3.02  -0.12 (-3.76%)

Fundamental Rating

2

Overall MDXH gets a fundamental rating of 2 out of 10. We evaluated MDXH against 73 industry peers in the Biotechnology industry. Both the profitability and financial health of MDXH have multiple concerns. MDXH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MDXH had negative earnings in the past year.
In the past 5 years MDXH always reported negative net income.
MDXH had a negative operating cash flow in each of the past 5 years.
MDXH.BR Yearly Net Income VS EBIT VS OCF VS FCFMDXH.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

MDXH's Return On Assets of -51.61% is on the low side compared to the rest of the industry. MDXH is outperformed by 63.64% of its industry peers.
The Return On Equity of MDXH (-393.48%) is worse than 75.32% of its industry peers.
Industry RankSector Rank
ROA -51.61%
ROE -393.48%
ROIC N/A
ROA(3y)-55.15%
ROA(5y)-64.23%
ROE(3y)-343.17%
ROE(5y)-262.12%
ROIC(3y)N/A
ROIC(5y)N/A
MDXH.BR Yearly ROA, ROE, ROICMDXH.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300 -400

1.3 Margins

The Gross Margin of MDXH (59.66%) is better than 64.94% of its industry peers.
In the last couple of years the Gross Margin of MDXH has declined.
The Profit Margin and Operating Margin are not available for MDXH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-6.79%
MDXH.BR Yearly Profit, Operating, Gross MarginsMDXH.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MDXH has more shares outstanding
Compared to 1 year ago, MDXH has a worse debt to assets ratio.
MDXH.BR Yearly Shares OutstandingMDXH.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
MDXH.BR Yearly Total Debt VS Total AssetsMDXH.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -3.05, we must say that MDXH is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.05, MDXH is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
MDXH has a Debt/Equity ratio of 2.17. This is a high value indicating a heavy dependency on external financing.
MDXH's Debt to Equity ratio of 2.17 is on the low side compared to the rest of the industry. MDXH is outperformed by 75.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.17
Debt/FCF N/A
Altman-Z -3.05
ROIC/WACCN/A
WACC6.93%
MDXH.BR Yearly LT Debt VS Equity VS FCFMDXH.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

MDXH has a Current Ratio of 2.43. This indicates that MDXH is financially healthy and has no problem in meeting its short term obligations.
MDXH has a Current ratio (2.43) which is in line with its industry peers.
A Quick Ratio of 2.27 indicates that MDXH has no problem at all paying its short term obligations.
MDXH has a Quick ratio (2.27) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.43
Quick Ratio 2.27
MDXH.BR Yearly Current Assets VS Current LiabilitesMDXH.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

5

3. Growth

3.1 Past

MDXH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.81%.
The Revenue has grown by 66.59% in the past year. This is a very strong growth!
MDXH shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.77% yearly.
EPS 1Y (TTM)-16.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
Revenue 1Y (TTM)66.59%
Revenue growth 3Y46.47%
Revenue growth 5Y-1.77%
Sales Q2Q%73.48%

3.2 Future

MDXH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 51.91% yearly.
The Revenue is expected to grow by 27.69% on average over the next years. This is a very strong growth
EPS Next Y-6519.8%
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%
EPS Next 5Y51.91%
Revenue Next Year84.81%
Revenue Next 2Y47.5%
Revenue Next 3Y43.11%
Revenue Next 5Y27.69%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MDXH.BR Yearly Revenue VS EstimatesMDXH.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
MDXH.BR Yearly EPS VS EstimatesMDXH.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MDXH. In the last year negative earnings were reported.
Also next year MDXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDXH.BR Price Earnings VS Forward Price EarningsMDXH.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDXH.BR Per share dataMDXH.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

MDXH's earnings are expected to decrease with -49.87% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDXH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MDxHealth SA

EBR:MDXH (12/15/2023, 7:00:00 PM)

3.02

-0.12 (-3.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap82.41M
Analysts86.67
Price Target8.4 (178.15%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)86.3%
Min EPS beat(2)82.17%
Max EPS beat(2)90.44%
EPS beat(4)4
Avg EPS beat(4)88.67%
Min EPS beat(4)82.17%
Max EPS beat(4)98.56%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)64.31%
Min Revenue beat(2)6.24%
Max Revenue beat(2)122.37%
Revenue beat(4)4
Avg Revenue beat(4)65.41%
Min Revenue beat(4)6.24%
Max Revenue beat(4)122.37%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)814.71%
PT rev (3m)814.71%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-889.37%
EPS NY rev (3m)-731.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.5%
Revenue NY rev (3m)1.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.01
P/FCF N/A
P/OCF N/A
P/B 5.1
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.68
EYN/A
EPS(NY)-4.7
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.98
BVpS0.59
TBVpS-2.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.61%
ROE -393.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.66%
FCFM N/A
ROA(3y)-55.15%
ROA(5y)-64.23%
ROE(3y)-343.17%
ROE(5y)-262.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-6.79%
F-ScoreN/A
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 2.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.43
Quick Ratio 2.27
Altman-Z -3.05
F-ScoreN/A
WACC6.93%
ROIC/WACCN/A
Cap/Depr(3y)43.52%
Cap/Depr(5y)35.7%
Cap/Sales(3y)6.07%
Cap/Sales(5y)4.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
EPS Next Y-6519.8%
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%
EPS Next 5Y51.91%
Revenue 1Y (TTM)66.59%
Revenue growth 3Y46.47%
Revenue growth 5Y-1.77%
Sales Q2Q%73.48%
Revenue Next Year84.81%
Revenue Next 2Y47.5%
Revenue Next 3Y43.11%
Revenue Next 5Y27.69%
EBIT growth 1Y-41.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.18%
EBIT Next 3Y24.82%
EBIT Next 5Y22.55%
FCF growth 1Y-63.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.31%
OCF growth 3YN/A
OCF growth 5YN/A